Regeneron Pharmaceuticals Inc. (REGN) Earns “Buy” Rating from Roth Capital
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reiterated by stock analysts at Roth Capital in a note issued to investors on Wednesday. They presently have a $520.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price target would suggest a potential upside of 34.70% from the stock’s previous close.
REGN has been the subject of several other reports. Cowen and Company reissued a “hold” rating and set a $430.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Citigroup Inc. reissued a “buy” rating and set a $470.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 23rd. Vetr lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $422.08 price target on the stock. in a report on Wednesday, July 27th. Canaccord Genuity restated a “hold” rating and set a $450.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, June 17th. Finally, RBC Capital Markets restated an “outperform” rating and set a $648.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 4th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 3.20% during trading on Wednesday, hitting $373.71. 498,424 shares of the company traded hands. The firm has a market cap of $39.10 billion, a P/E ratio of 58.30 and a beta of 1.31. The firm has a 50 day moving average of $400.58 and a 200 day moving average of $392.25. Regeneron Pharmaceuticals has a one year low of $329.09 and a one year high of $592.59.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The business earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the business earned $2.89 earnings per share. The business’s quarterly revenue was up 21.4% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current fiscal year.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Friday, July 29th. The shares were sold at an average price of $425.00, for a total value of $903,125.00. Following the completion of the transaction, the director now owns 15,125 shares in the company, valued at approximately $6,428,125. The sale was disclosed in a filing with the SEC, which is available at this link. 10.40% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares during the period. Capital World Investors boosted its stake in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares during the period. Wellington Management Group LLP boosted its stake in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares during the period. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock worth $1,669,035,000 after buying an additional 92,467 shares during the period. Finally, State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock worth $1,080,272,000 after buying an additional 15,272 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.